Etomidate and midazolam for reduction of anterior shoulder dislocation: A randomized, controlled trial

Study objective: We determine whether patients with acute, anterior shoulder dislocation undergoing emergency department procedural sedation and analgesia (PSA) with intravenous etomidate would experience a reduced time of impaired consciousness when compared with a group of patients receiving intra...

Full description

Saved in:
Bibliographic Details
Published in:Annals of emergency medicine 2002-11, Vol.40 (5), p.496-504
Main Authors: Burton, John H., Bock, Anthony J., Strout, Tania D., Marcolini, Evie G.
Format: Article
Language:English
Subjects:
Adult
Biological and medical sciences
Conscious Sedation
Double-Blind Method
Etomidate - therapeutic use
Female
Humans
Hypnotics and Sedatives - therapeutic use
Hypnotics. Sedatives
Male
Medical sciences
Midazolam - therapeutic use
Middle Aged
Neuropharmacology
Pharmacology. Drug treatments
Prospective Studies
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Shoulder Dislocation - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Study objective: We determine whether patients with acute, anterior shoulder dislocation undergoing emergency department procedural sedation and analgesia (PSA) with intravenous etomidate would experience a reduced time of impaired consciousness when compared with a group of patients receiving intravenous midazolam. Methods: This study was a prospective, double-blinded, randomized, institutional review board-approved trial of ED patients with anterior shoulder dislocation. Patients were randomized to receive intravenous boluses of etomidate (0.1 mg/kg) or midazolam (0.033 mg/kg) during PSA. The primary outcome for comparison was PSA duration. Results: Forty-six patients with anterior shoulder dislocation were enrolled: 22 in the etomidate group and 24 in the midazolam group. Three patients sustained reduction without physician or sedative intervention. Two patients were excluded from protocol because of unavailable study drug or fracture dislocation. The median lowest modified postanesthetic recovery score observed during PSA was 5 (95% confidence interval [CI] 4 to 7) in the etomidate group and 6 (95% CI 6 to 7) in the midazolam group. The median time of PSA for patients receiving etomidate was 10 minutes (95% CI 8 to 15) compared with 23 minutes (95% CI 16 to 30) for patients receiving midazolam, with a difference between the group medians of 13 minutes (95% CI 5 to 22). Reduction success was achieved in 37 (90%) of 41 patients: 2 did not experience reduction with etomidate and 2 did not experience reduction with midazolam. There were 15 PSA complications reported. Conclusion: Etomidate provides effective PSA for reduction of ED patients with anterior shoulder dislocation. When compared with midazolam, etomidate use confers a significantly shorter period of PSA. [Ann Emerg Med. 2002;40:496-504.]
ISSN:0196-0644
1097-6760
DOI:10.1067/mem.2002.126607